<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779905</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-02-40</org_study_id>
    <nct_id>NCT04779905</nct_id>
  </id_info>
  <brief_title>Chronic Kidney Disease and Non-alcoholic Fatty Liver Diseases</brief_title>
  <acronym>NAFLD</acronym>
  <official_title>Assessment of Chronic Kidney Disease in Non Alcoholic Fatty Liver Disease(NAFLD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease&#xD;
      worldwide. This disease reportedly affects up to 30% of the general population in Western&#xD;
      countries, especially in patients with metabolic syndrome, obesity, and type II diabetes.&#xD;
      NAFLD is considered to be an independent risk factor for cardiovascular disease and there is&#xD;
      accumulating evidence to support a causative role in the development of chronic kidney&#xD;
      disease (CKD). So, we aim first to assess the prevalence of chronic kidney disease in NAFLD&#xD;
      patients, secondly to detect the association between hepatic fibrosis and CKD in NAFLD&#xD;
      patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted on 100 patients 70 patients diagnosed to has NAFLD by&#xD;
      ultrasonography presented to the outpatient clinic of Sohag University Hospital, and A&#xD;
      control group of 30 healthy volunteers who looks normal on ultrasonography from February 2021&#xD;
      to July 2021.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      All included patients will be subjected to:&#xD;
&#xD;
        1. Detailed history, complete general and systemic examination .&#xD;
&#xD;
        2. BMI will be calculated as follow&#xD;
&#xD;
        3. Abdominal Ultrasonography.&#xD;
&#xD;
        4. Laboratory investigations:&#xD;
&#xD;
           Fasting and post-prandial blood sugar Serum lipogram. Liver function tests. Serum&#xD;
           creatinine, Albumin -creatinine Ratio.&#xD;
&#xD;
        5. Calculation of estimated Glomerular Filtration Rate eGFR.&#xD;
&#xD;
        6. Liver stiffness measurements to detect degree of fibrosis and measurement of the degree&#xD;
           of steatosis using (Fibroscan)&#xD;
&#xD;
      Ethical considerations:&#xD;
&#xD;
      The study will be approved by The Ethical committee of Sohag Faculty of Medicine, Sohag&#xD;
      University.&#xD;
&#xD;
      The study protocol will be adherent to practice guidelines of the World Medical Association&#xD;
      Code of Ethics (Declaration of Helsinki).&#xD;
&#xD;
      After explanation about the nature of the procedures, possible complications, benefits, and&#xD;
      steps of the study, All patients will give a written informed consent for participating in&#xD;
      the study, performing abdominal ultrasound, taking blood samples, performing fibroscan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2021</start_date>
  <completion_date type="Actual">September 15, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>prevalence of chronic kidney disease in nafld patient</measure>
    <time_frame>February 2021 to July 2021</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>correlation of chronic kidney disease and degree of hepatic fibrosis in nafld patient</measure>
    <time_frame>February 2021 to July 2021</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">62</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Non-alcoholic Fatty Liver Diseases</arm_group_label>
    <description>patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>healthy volunteers who looks normal on ultrasonography</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>urinary albumbin/creatinine ratio</intervention_name>
    <description>detection of microalbuminuria in nafld patients</description>
    <arm_group_label>Non-alcoholic Fatty Liver Diseases</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>estimated glomerular filtration rate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be conducted on 100 patients 70 patients diagnosed to has NAFLD by&#xD;
        ultrasonography presented to the outpatient clinic of Sohag University Hospital, and A&#xD;
        control group of 30 healthy volunteers who looks normal on ultrasonography from February&#xD;
        2021 to July 2021&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of&#xD;
        Sohag University Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diabetic patients.&#xD;
&#xD;
          2. Hypertensive patients.&#xD;
&#xD;
          3. Other causes of chronic liver disease rather than NAFLD.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Radwa Farag, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sohag University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Amin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sohag University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shimaa Hemdan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sohag University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mona Mohammed Abdelrahman</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30. Review.</citation>
    <PMID>21623852</PMID>
  </reference>
  <reference>
    <citation>Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762.</citation>
    <PMID>22488764</PMID>
  </reference>
  <reference>
    <citation>Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90. doi: 10.1038/nrgastro.2013.171. Epub 2013 Sep 17. Review.</citation>
    <PMID>24042449</PMID>
  </reference>
  <reference>
    <citation>McCullough K, Sharma P, Ali T, Khan I, Smith WC, MacLeod A, Black C. Measuring the population burden of chronic kidney disease: a systematic literature review of the estimated prevalence of impaired kidney function. Nephrol Dial Transplant. 2012 May;27(5):1812-21. doi: 10.1093/ndt/gfr547. Epub 2011 Sep 29. Review.</citation>
    <PMID>21965592</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Mona Mohammed Abdelrhman</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Hepatic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

